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ABSTRACT
Objective: To evaluate growth factors and cytokines in samples 
of platelet-rich plasma obtained by three different centrifugation 
methods. Methods: Peripheral blood of six individuals with no 
hematological diseases, aged 18 to 68 years, was drawn to obtain 
platelet-rich plasma, using the open method and commercial 
columns by Medtronic and Biomet. The products obtained with 
the different types of centrifugation were submitted to laboratory 
analysis, including pro-inflammatory cytokines and chemokines 
by flow cytometry assays, the concentration of fibroblast growth 
factors-2 (FGF-2) and transforming growth factor-beta1 (TGF-β1). 
Results: The diverse separation methods generated systematically 
different profiles regarding number of platelets and leukocytes. The 
Medtronic system yielded a product with the highest concentration 
of platelets, and the open method, with the lowest concentration of 
platelets. The results of cytokine analysis showed that the different 
types of centrifugation yielded products with high concentrations of 
interleukin 8, interleukin 1β. The open system resulted in a product 
with high levels of interleukin 6. Other cytokines and chemokines 
measured were similar between systems. The product obtained with 
the open method showed higher levels of TGF-β1 in relation to other 
systems and low FGF-2 levels. Conclusion: The formed elements, 
growth factors and cytokines in samples of platelet-rich plasma 
varied according to the centrifugation technique used.
Keywords: Platelet-rich plasma; Cytokines; Intercellular signaling peptides 
and proteins; Centrifugation/methods
RESUMO
Objetivo: Avaliar fatores de crescimento e citocinas em amostras 
de plasma rico em plaquetas obtidas por três diferentes métodos 
de centrifugação. Métodos: Foi coletado sangue periférico de 
seis indivíduos, sem doença hematológica, com idades entre 18 e 
68 anos, para obtenção de plasma rico em plaquetas, utilizando o 
método aberto e sistemas comerciais das empresas Medtronic e 
Biomet. Os produtos obtidos com os diferentes tipos de centrifugação 
foram submetidos às análises laboratoriais, incluindo citocinas pró-
inflamatórias e quimiocinas, por meio de ensaios de citometria de 
fluxo, concentração do fator de crescimento fibroblástico-2 (FGF-2) 
e fator de crescimento transformador-beta1 (TGF-β1). Resultados: 
As diferentes centrifugações geraram perfis sistematicamente 
diferentes referentes ao número de plaquetas e de leucócitos. O 
sistema da Medtronic originou produto com a maior concentração 
de plaquetas, e o método aberto com a menor concentração de 
plaquetas. Os resultados da análise de citocinas demonstraram 
que os diferentes tipos de centrifugação originaram produtos com 
elevadas concentrações de interleucina 8 e interleucina 1β. O sistema 
aberto resultou em produto com elevados níveis de interleucina 6. As 
demais citocinas e quimiocinas mensuradas foram similares entre os 
sistemas. O produto obtido com o método aberto apresentou níveis 
superiores de TGF-β1 em relação aos demais sistemas e reduzidos 
níveis de FGF-2. Conclusão: Os elementos figurados, fatores de 
crescimento e citocinas, em amostras de plasma rico em plaquetas, 
variaram conforme a técnica de centrifugação utilizada.
Descritores: Plasma rico em plaquetas; Citocinas; Peptídeos e proteínas 
de sinalização intercelular; Centrifugação/métodos
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INTRODUCTION
Platelets are cell fragments derived from megakaryocytes, 
measuring approximately 2μm in diameter. Their 
structure contains some organelles, such as mitochondria, 
microtubules and granules (α, δ and λ). The α granules 
contain more than 30 bioactive proteins, including 
growth factors, cytokines, adhesion and other molecules, 
which play a fundamental role in homeostasis and tissue 
remodeling.(1,2) Platelet proteome analysis reveals that 
in response to activation by thrombin, human platelets 
release more than 300 different proteins.(2) These 
growth factors have a significant impact on the action of 
mesenchymal cells in the wound healing processes.(3-6) 
In addition, cytokines and chemokines - which may be 
present in platelet-rich plasma (PRP) - can assist in 
the modulation of inflammation and in the resolution 
of regenerative processes.(6-10) The use of platelets as a 
rich source of bioactive factors was first suggested as 
a supplement to allogeneic fibrin glue. However, the 
availability of growth factors in platelet concentrates 
aroused great interest in this method for inducing healing 
and tissue regeneration, which is considered a low-cost 
alternative,(11) although there has been a gradual 
change in the cost of the treatment in the last 10 years. 
A substitute for these platelet concentrates is PRP, a 
preparation from which leukocytes and erythrocytes are 
removed, preserving the platelets, which are elements of 
smaller size and weight.
The use of PRP has been proposed in several health 
care areas, particularly in orthopedics, sports medicine 
and dentistry, as a therapeutic adjuvant in tissue 
regeneration processes. Several investigators associated 
this type of clinical application of PRP with induction of 
bone formation or the acceleration of wound healing 
in tissues, such as ligaments, muscles or tendons.(4,12-15) 
However, the subject is controversial, since some reports 
reveal good results with the use of PRP,(16,17) whereas 
others indicate insufficient or negative results.(16-18)
Platelet-rich plasma is a volume of plasma that has 
a platelet concentration above the reference normal 
value. The average normal platelet count is 200,000 
platelets/μl, but after processing, a concentration of 
1,000,000 platelets/μl is expected in PRP, that is, a 
five-fold enrichment.(19,20) Since PRP is generally 
developed from autologous blood, it is considered 
safe for clinical application, for not reacting with the 
host nor transmitting diseases.(3,21) However, an 
uncontrolled variable is added to the proposed therapy 
when preparations derived from patients with immune 
and inflammatory diseases are used. There are few 
studies that consistently document the effects of PRP 
application in patients or even the composition of 
the preparations.(22) There is no clearer information 
available on treatment efficiency, duration of effects, 
incidence and type of adverse events. Moreover, 
there is no consensus on the optimal composition and 
the profile of the components present in the various 
PRP formulations and preparation methods.(20,22,23) 
Furthermore, several studies showing positive effects of 
PRP application actually included the use of autogenous 
bone, in addition to PRP, in the regeneration of skin 
and bone tissues.(15) One of the outstanding issues is 
the presence of red blood cells and white blood cells 
contaminating the PRP, and their role in the success 
or failure of treatment. Some studies show that the red 
blood cells present in intraarticular injections can lead to 
irritation of the synovial membrane, whereas leukocytes 
may be associated with both tissue protection and greater 
inflammation.(4) In fact, the presence of leukocytes 
appears to significantly increase inflammatory cytokines, 
changing the regenerative potential of PRP,(20,24) inducing 
pain and functional limitation. On the other hand, other 
studies show a possible antibacterial function of PRP.
There are several methods to obtain PRP from 
whole blood.(21,22) The open method, still considered 
as one of the most efficient, uses centrifugation with 
subsequent recovery of isolated plasma.(18) There are 
also columns for obtaining PRP, which are sold as 
kits with no specifications of their contents. In this 
study, we compared the PRP obtained by the open 
method with two commercial products, specifically 
the Magellan columns (Arteriocyte Medical System, 
Cleveland, Ohio, USA) and GPSIII (Biomet, Warsaw, 
Indiana, USA). We analyzed the blood samples before 
processing, and the PRP obtained after processing, as to 
the presence and count of formed elements, particularly 
the platelet count, concentration of transforming growth 
factor-beta1 (TGF-β1) and fibroblast growth factor-2 
(FGF-2), TGF-β1 and basic FGF-2. In addition, we 
measured the cytokines and chemokines involved in the 
healing process or with immunomodulatory potential, 
namely interleukin (IL) 1β, IL-6, IL-8, IL-10, tumor 
necrosis factor alpha (TNF-α), monocyte chemotactic 
protein-1 (MCP-1), macrophage inflammatory protein-1 
(MIP-1) and regulated on activation, normal T cell 
expressed and secreted (RANTES). The samples were 
obtained from patients undergoing surgery for injuries, 
with the rationale to assess whether there were or 
not pro- and anti-inflammatory factors present, and 
whether the PRP samples were free or not from formed 
elements possibly harmful to treatment.
OBJECTIVE
To evaluate the presence of growth factors and cytokines 
in samples of platelet-rich plasma, obtained by three 
different centrifugation methods.
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METHODS 
Obtaining platelet-rich plasma
Peripheral blood was drawn from six individuals 
undergoing surgery for rotator cuff injury, with no blood 
disease, aged 18 to 68 years, to obtain PRP by applying 
the open method and, in parallel, by using the Magellan 
and GPSIII columns. The first method is a platelet 
separation column used in a single centrifugation step, 
with no indication of contamination with erythrocytes, 
but with the information that leukocytes are present in 
the concentrate. The second column is used in a two-step 
protocol, in which PRP is recovered from the intermediate 
layer between the red cells and the supernatant. Volumes 
of 26mL and 60mL of peripheral blood were collected, 
respectively, for each kit. The samples were processed 
by the local representative of each brand, according to 
the protocol established by the manufacturers. These two 
brands have in common the fact that both prepare a PRP 
richer in leukocytes and platelets.(22)
For the analysis of the open system to obtain PRP, 
developed by Anitua et al.,(21) samples of 20mL of 
peripheral blood were collected with a 19 gauge needle 
into tubes containing sodium citrate, from four subjects 
aged from 54 to 63 years. The material was centrifuged 
at 650g for 8 minutes, at room temperature, and the 
plasma supernatant was collected from the third fraction, 
next to the leukocytes and erythrocytes, a fraction rich 
in platelets and bioactive factors, but trying to avoid 
collection of leukocytes.(25)
Afterwards, within a maximum period of one hour 
after collecting the PRP samples by three different 
methods, the samples were evaluated in a clinical 
laboratory, with no thrombin activation or treatment 
with calcium chloride to induce formation of fibrin. The 
remaining samples were stored at -20°C until analysis.
The study was conducted in full compliance with 
the guidelines of the Research Ethics Committee of the 
Hospital Israelita Albert Einstein, under protocol 07/733, 
CAAE: 0182.0.028.000-07. The samples were collected 
after obtaining written Informed Consent from all donors.
Laboratory analysis of the components of the platelet-rich 
plasma
The following parameters were measured in the PRP 
samples: concentration of platelets, leukocytes and 
erythrocytes, mean platelet volume (MPV), hemoglobin 
and hematocrit, in the clinical laboratory of the Hospital 
Israelita Albert Einstein.
Analysis of growth factors 
The growth factors FGF-2 (basic) and TGF-β1 were 
measured using Quantikine Human FGF basic 
Immunoassay kit (R&D) and Human TGF-β1 ELISA 
Set, (BD OptEIA™), respectively, following the 
manufacturer instructions. A volume of 100μL of 
each sample was incubated with RD1-43 reagent or 
Ab capture buffer for 2 hours (after activation with 
1N HCl, at a dilution of 1:25 for 60 minutes at 4°C, 
followed by neutralization with 1N NaOH 1:25) at 
room temperature. After washing, the samples were 
incubated with conjugated FGF-2 or TGF-β1 substrate 
for 30 minutes. The reaction was stopped by adding the 
stop solution and absorbance readings were obtained in 
a microplate reader (DTX 880 Multimode Detector - 
Beckman Coulter, Inc.) at a wavelength of 450nm for 
FGF-2, and 570nm for TGF-β1. 
Analysis of inflammatory cytokines
The analysis of inflammatory cytokines and chemokines 
were performed using the Cytometric Bead Array 
(CBA) method, with Human Inflammatory Cytokines 
(IL-8, IL-1β, IL-6, IL-10, TNF, IL-12p70) and Human 
Chemokine (IL-8, RANTES, MIG, MCP-1, IP-10) kits, 
both from BD Pharmingen (San Diego, CA), following 
the manufacturer instructions. In short, a serial dilution 
curve was prepared using a standard sample of cytokines. 
For the reaction, volumes of 50μL of each sample were 
incubated with a specific mixture of beads for each of 
the analytes, followed by a reaction with the secondary 
antibody conjugated with PE Detection reagent, for 
one hour, at room temperature. Then the samples were 
washed and resuspended with wash buffer, and analyzed 
by flow cytometry (FACSAria, BD Biosciences, San 
Jose, CA). Data were analyzed using the FlowJo 
(TreeStar, Ashland, OR) and the BD CBA softwares.
Statistical analysis
Mean and standard error were calculated for all 
variables, using the GraphPad Prism software version 6 
(GraphPad Software, Inc., La Jolla, CA). The analysis 
of variance (ANOVA) for nonparametric data was used 
to assess the variables. The p values <0.05 were defined 
as level of significance.
RESULTS
The profile and composition of the platelet concentrate 
obtained by the three methods are displayed in table 1. 
Significant differences were observed in the PRP 
composition of the six samples submitted to different 
methods. Despite the variability among the samples, 
the two columns generated systematically different 
profiles for each sample with regard to the number of 
platelets and leukocytes. The highest concentration of 
einstein. 2016;14(3):391-7
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platelets was obtained using the Magellan column, on 
average 2.7 (2.11 to 3.95) times larger than GPSIII. 
The data indicated a concentration of only 1.5 times 
obtained with GPSIII column, whereas the Magellan 
column was able to concentrate the platelets about 5 
times. However, there was no difference in the mean 
platelet volume in any samples, indicating an absence of 
platelet lysis, a factor that may explain the lower values. 
Cytokines and chemokines
The results of cytokine and chemokine analyses are 
shown in figures 2 and 3, respectively. The amounts of 
cytokines were similar in the samples obtained by the 
three methods. In the samples obtained with GPSIII, 
this rate was even higher when compared to the 
Magellan samples (Figure 2A). The same occurred in 
relation to IL-1β, because the samples obtained with 
GPSIII showed a significantly greater amount than the 
other groups (Figure 2B). On the other hand, although 
the platelets have not been recovered with the open 
method, the IL-6 levels observed were consistently 
higher in the latter method than in the other two (Figure 
2C). The other cytokines, IL-10, TNF-α and IL-12p70 
(Figures 2D, 2E and 2F), were similar in the three types 
of samples. 
Table 1. Profile and composition of the platelet concentrate
System Platelets Mean volume (mL)
Leukocytes 
(x 103/µL)
Hematocrit 
(%)
Hemoglobin 
(g/dL)(x 103/µL)
GPS III 606.33±84.7 6.7±1.3 25.03±1.9 14.23±5.1 5.65±1.4
Magellan 1630.25±271 6.4±1.3 12.96±1.87 6.96±1.4 3.1±0.6
Open 55±8.6 5.65±0.27 0.6±0.2 0.025±0 0.13±0.1
Reference values for platelets: from 150 to 450 x 103/µL; for mean volume: from 6.5 to 11mL; (n=6).
Analysis of TGF-β1 and FGF-2 growth factors 
Despite the low number of platelets in the PRP 
prepared by the open method, the resulting product 
contained the desired bioactive molecules. In fact, the 
TGF-β1 concentration observed was the largest of the 
three preparations. 
The presence of FGF-2 (Figure 1A) also showed 
high variability, but mostly inverted, in relation to 
TGF-β1 (Figure 1B).
* p value <0.05; ** p value <0.01. 
TNF-α: tumor necrosis factor alpha; IL: Interleukin levels.
Figure 2. Interleukin levels in platelet-rich plasma measured by Magellan (n=6), 
GPSIII (n=6), and open (n=4) methods. (A) IL-8; (B) IL-1β; (C) IL-6; (D) IL-10; (E)
tumor necrosis factor (TNF-α); (F) IL-12p70
A
C
E
B
D
F
*Comparison of open system versus GPSIII, p <0.05. 
TGF-β1: transforming growth factor-beta1; FGF-2:fibroblast growth factors-2. 
Figure 1. Growth factors concentration. (A) transforming growth factor beta 1 
and (B) fibroblast growth factor 2 analyzed in platelet-rich plasma obtained by 
Magellan (n=6), GPSIII (n=6), and open (n=4) methods 
A
B
The results show the presence, albeit moderate, of 
MIG, MCP-1, and IP-10 chemokines in the concentrates 
obtained by the three methods (Figure 3A, 3B and 3C), 
unlike RANTES, in which they were present in larger 
amounts than expected, especially in the samples obtained 
by the open system (Figure 3D).
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DISCUSSION
The results of this study show a wide variation, 
depending on the type of preparation, even in the same 
collected sample. One wonders, after all, what is the 
desired composition of a PRP? Above all, what are 
the unwanted components that can cause side effects 
and tissue damage when they are used? It has been 
described that the final content of the PRP obtained 
from commercial methods has a higher concentration 
of red blood cells, which apparently does not induce 
inflammatory complications due to some tissue reaction 
to red blood cells.(26,27) However, in this study the 
application in orthodontic treatment was tested, thus 
enabling different inflammatory effects according to 
the tissue assessed. In fact, in the case of skeletal muscle 
repair, it is recommendable to avoid contamination 
with red blood cells. The iron contained in the heme 
molecules catalyzes the formation of free radicals, which, 
in turn, can induce not only bacterial death, but also 
apoptosis of tissue cells in response to pro-inflammatory 
signaling.(28) The number of erythrocytes and leukocytes 
present in the GPSIII preparation was almost twice as 
that found in the Magellan column preparation. The 
latter, in contrast, produced samples with a platelet 
concentration three times greater, in the recommended 
range, when compared to other methods. 
On the other hand, the mean platelet volume 
remained proportional in all methods, indicating that 
the final concentration obtained is not an artifact due 
to platelet lysis during the centrifugation process. It 
was clear that a different final product is obtained 
in each method. We concluded, therefore, that the 
differences in the number of platelets observed are due 
to the composition of the columns, or to the procedures 
indicated by the manufacturer. The open method 
resulted in a preparation with the lowest concentration 
of platelets, which was an unexpected result. During the 
open process, there appears to be a loss of platelets, but 
it was impossible to specify the reason, since the loss was 
significant. In the accepted definition of PRP, it should 
contain at least 200,000 platelets/μL.(28) Nevertheless, 
in the samples obtained by the open system, the other 
analyzes were performed to assess whether these 
preparations, despite the low concentration of platelets, 
contained or not the factors considered important for the 
desired therapeutic effect. It is important to note that 
the product obtained with the GPSIII column showed a 
significantly higher number of leukocytes compared to 
the Magellan column, and the same occurred with the 
hematocrit. There was also high levels of hemoglobin 
in the PRP samples prepared with two commercial 
columns (Magellan and GPSIII).(26,29)
In contrast, the measurement of TGF-β1 and FGF-2 
growth factors levels showed an increased TGF-β1 
level only in the preparation obtained using the open 
system, indicating that the concentration of TGF-β1 
and FGF-2 growth factors in the PRP it is not necessarily 
related to the mass of the recovered platelets. This 
result contrasts with previous studies that suggest a 
direct relation between the concentration of platelets 
and other formed elements in the preparations, and 
TGF-β1 and FGF-2 levels.(3,24) The higher concentration 
of TGF-β1 found in the PRP obtained with the open 
system may have been due to the circulating TGF-β1 
in plasma. On the other hand, it is well-known that 
obtaining reproducible measurements of TGF-β1 is 
very difficult.(30) Some studies indicate serum levels 
in the range of 0.1 to 25ng/mL(29,30) or approximately 
5ng/mL.(31) In comparison, the values obtained in our 
study are much lower. According to Veselý et al.,(31) FGF-2 
is normally undetectable in serum, with very low values, 
as we observed. However, although they are classified 
as generators of leukocyte-rich PRP,(22) thus having the 
potential to produce larger quantities of TGF-β1, only 
the GPS III preparation reached statistically significant 
levels compared to the open system. The wide variation 
of data, even in triplicate simultaneous analyses, indicates 
that the variation in these values should not have 
great biological significance. In fact, the normal serum 
levels of TGF-β1 reported in the literature range from 
4.83 to 55.05ng/mL,(31) confirming that all the values of 
TGF-β1 obtained are, in fact, lower than the expected. 
The values measured in this study are equivalent to those 
* p value <0.05.
MIG: monokine induced by gamma; MCP: monocyte chemotactic protein; IP: inducible protein; RANTES: regulated on 
activation, normal T cell expressed and secreted.
Figure 3. Chemokine levels measured in platelet-rich plasma samples by Magellan 
(n=6), GPSIII (n=6), and open (n=4) methods
A B
DC
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obtained by other authors(29) and probably correspond 
to the platelet TGF-β1, because the plasma samples were 
subjected to an activation process to release TGF-β1 
dimerized with latency-associated peptide (LAP).(30)
In parallel, our results show that obtaining PRP 
by the three methods described produces considerable 
amounts of IL-6, IL-1β, IL-8 and TNF-α. All PRP 
samples showed high IL-8 levels as compared to the 
reference values reported in literature, that is, 1.2 to 
1.5ng/L.(24,26) Fibroblast proliferation, with matrix 
production and fibrous scarring, is a major characteristic 
of the final stages of healing, and various growth factors 
have been studied with a possible role in improving the 
healing of target tissues.(32) The fibroblasts proliferate 
in response to stimulation by cytokines and factors, 
such as IL-1, IL-6, IL-4, TNF-α, FGF-2 and TGF-β1 
- precisely the factors released by the platelets and, 
for this reason, measured in this study. These results 
suggest that the use of PRP in cartilaginous tissue can 
cause a strong pro-inflammatory effect. In fact, it was 
shown that IL-6 is associated with pro-inflammatory 
mechanisms in cartilage and, with IL-1 and TNF-α, 
participates in the cartilage degradation mechanism.(33) 
Moreover, IL-6 and TNF-α are also associated with 
the healing of muscle injury,(34) and TGF-β1, through 
IL-6, participates in transdifferentiation of fibroblasts 
into myofibroblasts.(35) However, it is important to note 
that, in this study, the TGF-β1 levels did not follow 
the high IL-6 values observed. Finally, IL-10, which 
is considered an anti-inflammatory cytokine, was also 
present in concentrations higher than expected.(36) 
There is consensus that circulating IL-10 values may 
vary widely and, in particular, they increase in response 
to inflammatory stimuli.(36-38)
These considerations are important, particularly 
because the samples were obtained from patients with 
surgical indication for the treatment of rotator cuff injury 
and, therefore, probably presenting active inflammatory 
process. Thus, it is possible that individuals treated 
with anti-inflammatory drugs, patients with other 
lesions, or even those with no active processes, generate 
preparations with profiles that are very different from 
those we observed. 
It becomes increasingly important to validate 
the use of PRP, assessing its application in specific 
diseases, by selecting the target tissues and controlling 
the heterogeneity of the patients according to their 
demographic characteristics. Clinical trials should also 
include the optimization of the preparation, by choosing 
the best method, the dosage of components present in 
the preparations, volume of the concentrate, number of 
applications, whether or not to include leukocytes, and 
any other confounding factors that may render the use 
of PRP controversial.(39) A recent study reviewed the 
published clinical trials on the clinical use of PRP in 
the treatment of musculoskeletal injuries, and concluded 
that there is insufficient evidence for the use of this 
therapy. According to the authors, the standardization 
of PRP preparation methods is one of the critical points 
that prevents efficacy of clinical use of PRP from being 
confirmed.(40)
Our results corroborate the literature, demonstrating 
that diverse PRP preparation methodologies generate 
products with completely different compositions, both 
in regard with formed elements and cytokines and 
growth factors, which probably result in totally different 
therapeutic effects, hindering the clinical assessment of 
PRP. 
CONCLUSION
To date, the clinical use of platelet-rich plasma has not 
yet presented reliable evidence and proven efficacy, in 
part due to the absence of clear methodology standards 
for obtaining and characterizing it. The concentration 
of formed elements, growth factors and cytokines in 
samples of platelet-rich plasma varied according to the 
centrifugation method utilized. The method using the 
Magellan system resulted in a preparation with higher 
platelet concentration, a main feature of the platelet-rich 
plasma, but with variability in the concentration of growth 
factors and cytokines. The validation of the therapeutic 
use of platelet-rich plasma requires strictly controlled 
clinical trials, regarding the method for obtaining it 
and the characteristics of the donors. Knowledge about 
the composition of the different preparations should 
contribute to the associations of the use of platelet-rich 
plasma with the patients’ clinical outcomes.
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